Abhydrolase Domain Containing 6 (ABHD6) Antibody (FITC)

Background

ABHD6 is a serine hydrolase that modulates lipid signaling by hydrolyzing monoacylglycerols, including 2-arachidonoylglycerol (2-AG), a key endocannabinoid. Through its regulation of 2-AG levels, ABHD6 influences cannabinoid receptor signaling, which affects processes such as pain perception, appetite, and inflammation. ABHD6 is expressed in multiple tissues, including the brain, pancreas, and immune cells, where it plays roles in synaptic activity, glucose homeostasis, and immune responses. It has also been implicated in neuroinflammation and metabolic disorders, with potential links to diseases such as Alzheimer’s and diabetes. Structurally, ABHD6’s hydrolase domain is specialized for monoacylglycerol hydrolysis, making it a key regulator of endocannabinoid tone. As a critical enzyme in lipid signaling and metabolism, ABHD6 is a promising therapeutic target for treating neurodegenerative diseases, metabolic conditions, and chronic pain.